Why Johnson & Johnson (JNJ) Stock Just Hit Its Highest Price Ever
TLDR
- JNJ hit an all-time high of $275.48, with a market cap of $661 billion
- The stock is up 53% over the past year, with a total return of 56.29%
- Q2 sales rose 6.6% to $25.31 billion; adjusted EPS came in at $2.90
- Management raised its 2026 revenue outlook to approximately $101.1 billion
- Multiple analysts raised price targets, with Guggenheim setting a $287 target
Johnson & Johnson hit a new all-time high of $275.48 on Tuesday, August 19, pushing its market cap to $661 billion. The stock has gained 53% over the past year.
The move follows a strong second quarter. Q2 sales rose 6.6% to $25.31 billion, and adjusted earnings came in at $2.90 per share. Those numbers beat expectations and gave management the confidence to raise its 2026 outlook.
JNJ now targets roughly $101.1 billion in full-year revenue and $11.68 in adjusted earnings per share at the midpoint. That puts it close to a milestone few healthcare companies ever reach: $100 billion in annual sales.
The rally was partly driven by a broader rotation. As the Nasdaq faced selling pressure Tuesday, investors moved into defensive names. JNJ was one of the clearest beneficiaries, jumping around 3% to $270.19 before pushing to fresh highs the following day.
โฆ Continue reading the full article at the original source below.
